{"id":92711,"date":"2024-02-12T14:23:14","date_gmt":"2024-02-12T13:23:14","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/"},"modified":"2025-10-13T15:03:26","modified_gmt":"2025-10-13T13:03:26","slug":"financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/","title":{"rendered":"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics"},"content":{"rendered":"<p><strong>El consorcio p\u00fablico-privado formado por la empresa biotecnol\u00f3gica<a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/connecta-therapeutics\/\" target=\"_blank\" rel=\"noopener\"> CONNECTA Therapeutics<\/a>, el <a href=\"https:\/\/www.crg.eu\/en\" target=\"_blank\" rel=\"noopener\">Centro de Regulaci\u00f3n Gen\u00f3mica (CRG)<\/a>, el <a href=\"https:\/\/www.imim.es\/es_index.html\" target=\"_blank\" rel=\"noopener\">Instituto de Investigaci\u00f3n del Hospital del Mar<\/a> y el <a href=\"https:\/\/www.tauli.cat\/es\/institut\/\" target=\"_blank\" rel=\"noopener\">Instituto de Investigaci\u00f3n e Innovaci\u00f3n Parc Taul\u00ed (I3PT)<\/a> ha conseguido 2,7 millones de euros de financiaci\u00f3n\u00a0del Ministerio de Ciencia, Innovaci\u00f3n y Universidades y de la Uni\u00f3n Europea, a trav\u00e9s del\u00a0programa Next Generation EU, para\u00a0iniciar los ensayos cl\u00ednicos de Fase IIa del f\u00e1rmaco CTH120 dirigido al tratamiento del s\u00edndrome X fr\u00e1gil\u00a0(SXF).<\/strong><\/p>\n<p>La financiaci\u00f3n procedente de la convocatoria competitiva \u00abProyectos de colaboraci\u00f3n p\u00fablico-privada\u00bb complementa la inversi\u00f3n privada de los inversores de <a href=\"https:\/\/connectatherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">CONNECTA Therapeutics<\/a> como Prous Institute for Biomedical Research, Inveready y CDTI Innvierte, y la obtenida a trav\u00e9s de los programas de financiaci\u00f3n p\u00fablica Retos Colaboraci\u00f3n, CDTI NEOTEC y ENISA.<\/p>\n<p>CTH120 es una terapia innovadora dise\u00f1ada mediante t\u00e9cnicas de inteligencia artificial que act\u00faa como modulador de la neuroplasticidad. Actualmente se est\u00e1n finalizando los ensayos cl\u00ednicos de Fase I por CTH120 en el Instituto de Investigaci\u00f3n del Hospital del Mar de Barcelona, \u200b\u200bliderados por el <strong>Dr. Rafael de la Torre <\/strong>y la<strong> Dra. Ana Aldea<\/strong> como principales investigadores.<\/p>\n<p>La previsi\u00f3n es disponer de los resultados finales del ensayo cl\u00ednico de Fase I durante el primer semestre de este a\u00f1o y poder\u00a0iniciar la Fase IIa en el primer semestre de 2025. En esta nueva fase,\u00a0el I3PT, con la<strong> Dra. Ana Roche<\/strong> como investigadora principal, se une como partner estrat\u00e9gico\u00a0junto con el CRG y el Instituto de Investigaci\u00f3n del Hospital del Mar. Durante el proyecto tambi\u00e9n se identificar\u00e1n biomarcadores espec\u00edficos para facilitar la valoraci\u00f3n de la respuesta al tratamiento, actividad liderada por la <strong>Dra. Mara Dierssen<\/strong> en el CRG.<\/p>\n<p>\u201cNos alegra anunciar esta noticia a pocos d\u00edas de la celebraci\u00f3n del D\u00eda Mundial de las Enfermedades Raras, cuyas terapias son un gran desaf\u00edo para la salud p\u00fablica. Esta financiaci\u00f3n del Ministerio de Ciencia, Innovaci\u00f3n y Universidades nos permite progresar en el desarrollo cl\u00ednico de un tratamiento espec\u00edfico para el SXF con centros e investigadores de prestigio internacional en el campo de las neurociencias en el \u00e1rea de Barcelona\u201d, comenta <strong>Jordi F\u00e0brega<\/strong>, CEO y cofundador de CONNECTA Therapeutics.<\/p>\n<h3><strong>Un first-in-class para tratar la primera causa de discapacidad intelectual hereditaria<\/strong><\/h3>\n<p>El s\u00edndrome X fr\u00e1gil (SXF) es un trastorno gen\u00e9tico hereditario ligado al cromosoma X que causa discapacidad intelectual y problemas emocionales y sociales, de leves a graves como hiperactividad, ansiedad, comportamientos agresivos o autismo. Su prevalencia se estima en aproximadamente 3 pacientes por cada 10.000 habitantes y se diagnostica durante los primeros meses de vida o primera infancia mediante pruebas sangu\u00edneas de ADN. No existe un tratamiento espec\u00edfico dirigido a la causa de la patolog\u00eda, s\u00f3lo tratamientos que ayudan a paliar los s\u00edntomas. Actualmente, la SXF es la primera causa de discapacidad intelectual hereditaria y la segunda causa gen\u00e9tica m\u00e1s prevalente despu\u00e9s del s\u00edndrome de Down.<\/p>\n<p>El s\u00edndrome X fr\u00e1gil se debe a una mutaci\u00f3n que comporta la falta de la prote\u00edna FMRP, con un papel importante en la neuroplasticidad y la maduraci\u00f3n de las conexiones sin\u00e1pticas entre neuronas, hechos que est\u00e1n relacionados con la discapacidad intelectual y la sintomatolog\u00eda de los pacientes.<\/p>\n<p>El f\u00e1rmaco CTH120 de CONECTA Therapeutics, dise\u00f1ado mediante t\u00e9cnicas de inteligencia artificial, ha demostrado en estudios precl\u00ednicos desarrollados en el grupo de la<strong> Dra. Mara Dierssen<\/strong> del Centro de Regulaci\u00f3n Gen\u00f3mica de Barcelona fue un buen modulador de la neuroplasticidad, a la vez que mejora la capacidad cognitiva y restaura manifestaciones conductuales como los problemas de interacci\u00f3n social. CTH120 cuenta con la designaci\u00f3n de medicamento hu\u00e9rfano de la Agencia Europea del Medicamento.<\/p>\n<p><strong>\u00bb M\u00e1s informaci\u00f3n:<\/strong>\u00a0<a href=\"https:\/\/connectatherapeutics.com\/news\/connecta-therapeutics-crg-hospital-del-mar-research-institute-and-i3pt-receive-e2-7-million-from-the-spanish-ministry-of-science-and-innovation-to-begin-phase-iia-trials-for-cth120-in-fragile-x-synd\/\" target=\"_blank\" rel=\"noopener\">web de CONNECTA Therapeutics [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El consorcio p\u00fablico-privado formado por la empresa biotecnol\u00f3gica CONNECTA Therapeutics, el Centro de Regulaci\u00f3n Gen\u00f3mica (CRG), el Instituto de Investigaci\u00f3n del Hospital del Mar y el Instituto de Investigaci\u00f3n e&#8230;<\/p>\n","protected":false},"author":14,"featured_media":92756,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[345],"tags":[],"class_list":["post-92711","post","type-post","status-publish","format-standard","has-post-thumbnail","category-financiacion"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El consorcio p\u00fablico-privado formado por la empresa biotecnol\u00f3gica CONNECTA Therapeutics, el Centro de Regulaci\u00f3n Gen\u00f3mica (CRG), el Instituto de Investigaci\u00f3n del Hospital del Mar y el Instituto de Investigaci\u00f3n e...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-12T13:23:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/CONNECTATherapeutics-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"899\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics\",\"datePublished\":\"2024-02-12T13:23:14+00:00\",\"dateModified\":\"2025-10-13T13:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/\"},\"wordCount\":695,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/CONNECTATherapeutics-1.jpg\",\"articleSection\":[\"FINANCIACION\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/\",\"name\":\"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/CONNECTATherapeutics-1.jpg\",\"datePublished\":\"2024-02-12T13:23:14+00:00\",\"dateModified\":\"2025-10-13T13:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/CONNECTATherapeutics-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/CONNECTATherapeutics-1.jpg\",\"width\":899,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics - Parc Cient\u00edfic de Barcelona","og_description":"El consorcio p\u00fablico-privado formado por la empresa biotecnol\u00f3gica CONNECTA Therapeutics, el Centro de Regulaci\u00f3n Gen\u00f3mica (CRG), el Instituto de Investigaci\u00f3n del Hospital del Mar y el Instituto de Investigaci\u00f3n e...","og_url":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2024-02-12T13:23:14+00:00","article_modified_time":"2025-10-13T13:03:26+00:00","og_image":[{"width":899,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/CONNECTATherapeutics-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paula Ca\u00f1al","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics","datePublished":"2024-02-12T13:23:14+00:00","dateModified":"2025-10-13T13:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/"},"wordCount":695,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/CONNECTATherapeutics-1.jpg","articleSection":["FINANCIACION"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/","url":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/","name":"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/CONNECTATherapeutics-1.jpg","datePublished":"2024-02-12T13:23:14+00:00","dateModified":"2025-10-13T13:03:26+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/CONNECTATherapeutics-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/CONNECTATherapeutics-1.jpg","width":899,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/financiacion-de-27-me-para-la-fase-iia-del-farmaco-contra-el-sindrome-x-fragil-de-connecta-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Financiaci\u00f3n de 2,7 M\u20ac para la Fase IIa del f\u00e1rmaco contra el s\u00edndrome X fr\u00e1gil de CONNECTA Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/92711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=92711"}],"version-history":[{"count":3,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/92711\/revisions"}],"predecessor-version":[{"id":92714,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/92711\/revisions\/92714"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/92756"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=92711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=92711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=92711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}